Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amneal submits NDA to US FDA for Parkinson’s disease treatment
Amneal seeks FDA approval for IPX203 an oral formulation of CD/LD extended-release capsules to treat Parkinson’s disease. Credit: Steve Buissinne from Pixabay.
Amneal seeks FDA approval for IPX203 an oral formulation of CD/LD extended-release capsules to treat Parkinson’s disease. Credit: Steve Buissinne from Pixabay.